VWF anticorps (AA 1815-1939)

N° du produit ABIN4949942

Cet anticorps anti-VWF est un anticorps Souris Monoclonal détectant VWF dans WB, IP, FACS, IF et IHC (p). Adapté pour Humain.

Aperçu rapide pour VWF anticorps (AA 1815-1939) (ABIN4949942)

Antigène: VWF (Von Willebrand Factor (VWF))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp VWF est non-conjugé

Application: Western Blotting (WB), Immunoprecipitation (IP), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: VWF-1465

Détail du produit anti-VWF anticorps

Épitope: AA 1815-1939

Purification: Protein G affinity chromatography

Immunogène: Amino acids 1815-1939 from the human protein were used as the immunogen for this vWF antibody.

Isotype: IgG1

Information d'application

Indications d'application: The optimal dilution of the vWF antibody for each application should be determined by the researcher.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT,WB: 0.5-1 μg/mL,IP: 1-2 μg/500 μg lysate

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the vWF antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Détails sur VWF

Antigène: VWF (Von Willebrand Factor (VWF))

Autre désignation: von Willebrand Factor / vWF

Sujet: Von Willebrand Factor (vWF) is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi's sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.